An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.
The researchers said that they are developing a fiber probe that could generate a Bessel beam that could be inserted into arteries to obtain internal images.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
Quanterix's Simoa single-molecule detection method combined with high-affinity antibodies detected minute levels of problematic interferon alpha proteins, a study said.
